Latest News
Stryker to Acquire Amplitude Vascular Systems, Adding Lithotripsy Technology to Vascular Portfolio
Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems, a privately held medical technology company developing a next-generation intravascular lithotripsy platform designed to treat calcified peripheral arterial disease....
Read More →Medtronic Sets June 3 Date for Fourth-Quarter and Full Fiscal Year 2026 Results
Medtronic has announced it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. The fiscal year ends on Friday, April 24,...
Read More →EU Approves Dupixent as First Targeted Treatment for Young Children with Chronic Spontaneous Urticaria
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years who have not responded adequately to antihistamines and are naive...
Read More →Novartis Expands Community Health Programs to 30-Plus Countries by 2030 to Address Heart Disease and Cancer Gaps
Novartis has announced plans to expand its community health initiatives from 11 to over 30 countries by 2030, targeting underserved populations with heart disease and cancer. The expansion encompasses three...
Read More →Abbott Survey Reveals Gap Between Americans' Belief in Disease Prevention and Their Health Confidence
A new survey commissioned by Abbott and conducted by Kantar among 4,000 U.S. adults has uncovered a significant disconnect between what Americans believe about chronic disease prevention and how confident...
Read More →Sanofi's Bispecific Antibody Lunsekimig Meets Key Endpoints in Asthma and Nasal Polyp Studies
Sanofi has announced positive Phase 2 results for lunsekimig, a bispecific antibody designed to simultaneously block TSLP and IL-13, in two respiratory studies. The AIRCULES Phase 2b study met its...
Read More →EU Approves Sanofi's Rezurock for Chronic Graft-Versus-Host Disease
The European Commission has granted conditional marketing authorization for Sanofi’s Rezurock (belumosudil), a selective ROCK2 inhibitor, to treat chronic graft-versus-host disease in patients aged 12 and older weighing at least...
Read More →Abbott Integrates Precision Oncology Tests Into Flatiron's OncoEMR Platform
Abbott and Flatiron Health have announced the integration of Abbott’s Precision Oncology test portfolio into OncoEMR, Flatiron’s cloud-based electronic medical record platform. The integration enables oncology providers to digitally order...
Read More →Novartis's Fabhalta Slows Kidney Function Decline by Nearly 50% in IgA Nephropathy Trial
Final two-year results from the Phase III APPLAUSE-IgAN study show that Novartis’s Fabhalta (iptacopan) slowed the decline of kidney function by 49.3% compared to placebo in patients with IgA nephropathy,...
Read More →Sanofi's Amlitelimab Shows Positive Phase 3 Results in Atopic Dermatitis at AAD Meeting
Sanofi has reported positive Phase 3 trial results for amlitelimab, a monoclonal antibody targeting OX40-ligand, in treating moderate-to-severe atopic dermatitis. The data were presented in a late-breaking session at the...
Read More →EU Panel Recommends Approval of Sanofi's Sarclisa Subcutaneous Formulation for Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of a subcutaneous formulation of Sanofi’s Sarclisa (isatuximab) for treating multiple myeloma across all currently approved...
Read More →Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Generation Anti-IgE Therapy
Novartis has agreed to acquire Excellergy, Inc., a private biotech developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments. The deal’s lead asset, Exl-111, is...
Read More →